Ab&B Bio-Tech (HKEX: 02627), a pioneer in next-generation vaccine development and HLC portfolio company, today completed its highly anticipated listing on the Hong Kong Stock Exchange. The IPO closed its first trading day at HKD 33.62 per share, representing a 160.6% increase from its offering price of HKD 12.90.

Ab&B Bio-Tech's HKEX debut achieved 4,000x oversubscription in its public offering, with total bids exceeding HKD 210 billion, making it 2025’s most oversubscribed IPO in Hong Kong to date.

This milestone is a testament to Ab&B team’s work in vaccine innovation and the market’s confidence in their scalable platform. HLC is proud to have supported this journey from the early on and is more excited for the next chapter of growth!